12:23 PM
 | 
Dec 06, 2018
 |  BC Extra  |  Company News

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to treat amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) mutations.

Biogen, which...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >